ImmunityBio, Inc. IBRX Reportable Segment — Operating Income (Loss)
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s reportable segment — operating income (loss).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s reportable segment — operating income (loss)?
- ImmunityBio, Inc. (IBRX) reported reportable segment — operating income (loss) of -$69.79M in Q1 2026.
- How has ImmunityBio, Inc.'s reportable segment — operating income (loss) changed year-over-year?
- ImmunityBio, Inc.'s reportable segment — operating income (loss) decreased by 8.3% year-over-year, from -$64.43M to -$69.79M.
- What is the long-term trend for ImmunityBio, Inc.'s reportable segment — operating income (loss)?
- Over 2 years (2023 to 2025), ImmunityBio, Inc.'s reportable segment — operating income (loss) has grown at a -15.9% compound annual growth rate (CAGR), from -$362.25M to -$256.03M.
- What does reportable segment — operating income (loss) mean?
- The profit or loss generated by a specific business segment.
- How do you interpret reportable segment — operating income (loss)?
- Higher values indicate better operational efficiency or successful monetization of assets within the segment.
- How does reportable segment — operating income (loss) compare across companies?
- Commonly reported as segment operating profit or loss in segment reporting disclosures.